Now is the time to make MART moves for asthma. We have been using the separate blue (reliever) and brown (preventer) inhalers for far too long. The National Review of Asthma Deaths (NRAD) came out a decade ago, yet as a nation, we still have the highest asthma death rate in Europe. This is unsurprising, considering many patients still rely on their blue inhalers alone. However,
Maintenance and reliever therapy (MART) is a treatment for asthma where a single combined inhaler is used for both maintenance and reliever purposes, instead of having separate preventer (brown) and reliever (blue) inhalers.
The asthma slide rule helps to start a conversation with your patients and colleagues around how much salbutamol is acceptable before a review is necessary
The captain of your asthma care should be your regular preventer inhaler, not the co-pilot blue inhaler.
Succinct guidance on the key elements of a good respiratory review for people with asthma
In these three case studies, clinicians explain how practices can help their patients to reduce their over reliance on short-acting beta2 agonists (SABA)
The playing cards on these slides and downloadable PDF playing cards are a way to trigger conversations with healthcare teams, and between pharmacists and patients regarding the use of/reliance on SABA inhalers. We invite you to use them to start a discussion!